A backdrop of harsh scrutiny on the industry explains sharp market reaction to investigation into UnitedHealth.
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s expected to curtail widespread access to cheaper copies of the popular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback